BCDA vs. LIFE, QURE, ADPT, LXEO, CABA, ALEC, TCRX, VYGR, OCGN, and EDIT
Should you be buying BioCardia stock or one of its competitors? The main competitors of BioCardia include aTyr Pharma (LIFE), uniQure (QURE), Adaptive Biotechnologies (ADPT), Lexeo Therapeutics (LXEO), Cabaletta Bio (CABA), Alector (ALEC), TScan Therapeutics (TCRX), Voyager Therapeutics (VYGR), Ocugen (OCGN), and Editas Medicine (EDIT). These companies are all part of the "medical" sector.
aTyr Pharma (NASDAQ:LIFE) and BioCardia (NASDAQ:BCDA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, community ranking, valuation and earnings.
BioCardia has higher revenue and earnings than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.
In the previous week, BioCardia had 1 more articles in the media than aTyr Pharma. MarketBeat recorded 4 mentions for BioCardia and 3 mentions for aTyr Pharma. BioCardia's average media sentiment score of 1.31 beat aTyr Pharma's score of 0.71 indicating that aTyr Pharma is being referred to more favorably in the media.
aTyr Pharma received 411 more outperform votes than BioCardia when rated by MarketBeat users. Likewise, 61.52% of users gave aTyr Pharma an outperform vote while only 50.00% of users gave BioCardia an outperform vote.
aTyr Pharma has a net margin of 0.00% compared to aTyr Pharma's net margin of -2,208.76%. BioCardia's return on equity of -56.92% beat aTyr Pharma's return on equity.
aTyr Pharma has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500. Comparatively, BioCardia has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500.
aTyr Pharma currently has a consensus price target of $23.67, suggesting a potential upside of 1,268.02%. BioCardia has a consensus price target of $60.00, suggesting a potential upside of 1,198.70%. Given BioCardia's stronger consensus rating and higher probable upside, equities research analysts plainly believe aTyr Pharma is more favorable than BioCardia.
61.7% of aTyr Pharma shares are held by institutional investors. Comparatively, 20.6% of BioCardia shares are held by institutional investors. 3.7% of aTyr Pharma shares are held by company insiders. Comparatively, 20.0% of BioCardia shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
aTyr Pharma beats BioCardia on 12 of the 18 factors compared between the two stocks.
Get BioCardia News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCDA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BCDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioCardia Competitors List
Related Companies and Tools
